Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: non-proportional hazards returned 14 record(s)
|
|
Sunday, 07/29/2018
|
Estimation in the Nested Case-Control Design Under Model Misspecification
Michelle Nuno; Daniel L. Gillen, University of California, Irvine
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
|
Estimation in the Nested Case-Control Design Under Model Misspecification
Michelle Nuno; Daniel L. Gillen, University of California, Irvine
2:35 PM
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
3:25 PM
|
Sample Size and Power Calculation for Immuno-Oncology Clinical Trials
Binbing Yu, MedImmune, Inc.; Dongyue FU, MedImmune, Inc.; Hefei (Harry) Yang, MedImmune, Inc.
4:20 PM
|
Design and Analysis of Survival Trials with Treatment Crossover
Xiaodong Luo, Sanofi
4:25 PM
|
Case Studies of Non-Proportional Hazards in Oncology and Hematology Trials
Jingjing Ye, FDA
4:45 PM
|
Design and Analysis of Cancer Immunotherapy Trials with Potential Violation of Proportional Hazards Assumption
Xiaofei Wang, Duke University School of Medicine; Guangyu Yang , University of Michigan
5:05 PM
|
|
Monday, 07/30/2018
|
Closed-Form Solutions for Group Sequential Design in Survival Trials with Non-Proportional Hazards
Jianliang Zhang, Medimmune, LLC; Erik Pulkstenis, AbbVie
10:05 AM
|
Practical Considerations on the Challenges to the Design and Analysis of Immuno-Oncology Trials
Yabing Mai, AbbVie, Inc; Yue Shentu, Merck and Co Inc
11:50 AM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:20 PM
|
|
|
